- Prev close
- $83.75
- Day range
- $81.49 – $83.27
GEHC’s +6.4% move was driven mainly by company-specific earnings and outlook news, not the broader tape; the setup looks broadly supported by 6.5% revenue growth, 12.9% operating margins, and a recent lift in guidance, though tariff and margin pressure remain the main watchpoints.
GEHC
GE HEALTHCARE TECHNOLOGY
As of Nov 5, 2026
74/100
Looks healthyHealth ScoreWhat drove the move
GEHC moved +6.4% while the S&P 500 rose +1.7% and the Nasdaq 100 rose +1.0%, so the stock outpaced the market by a wide margin. Same-sector peers were mixed to weaker — SYK -1.3%, BSX -2.6%, BDX +2.1%, and EW +1.5% — which argues against a pure sector move. The primary driver is stock-specific: the recent Q3 earnings call highlights say GEHC raised its 2026 earnings outlook on strong Q3 results, alongside new company news such as Tampa General Hospital expanding use of Allia Moveo and GE HealthCare leading Laza Medical’s up to $160 million Series B financing.
How to read the volatility
This looks like a large but explainable move, not ordinary noise. The business still shows 6.5% revenue growth on a TTM basis, 5.8% revenue growth in the latest quarter, gross margin of 39.5%, operating margin of 12.9%, and net margin of 9.3%. Valuation is not cheap at PE 18.4 and forward PE 14.2, and the PEG of 1.73 is not meaningful here because EPS growth is -11.0% YoY (TTM), so the market is paying for a growth profile that is uneven at the earnings line. Beta is 0.75, which normally points to lower day-to-day volatility, so a +6.4% session stands out as event-driven rather than routine. Analyst consensus is also constructive at 8 strong-positive, 13 positive, 8 neutral, 0 negative, and 0 strong-negative, which supports the move; the main offset is the stated tariff risks, fourth-quarter growth concerns, and margin pressures.
Earnings setup
The next earnings date isn’t available this period, so I can’t place the report on a calendar date. The most recent earnings commentary says GEHC raised its 2026 earnings outlook on strong Q3 results, while also flagging tariff risks, fourth-quarter growth concerns, and margin pressures. On the published fundamentals, the market is still looking at revenue growth of 6.5% TTM and 5.8% in the latest quarter, EPS of -11.0% YoY (TTM), gross margin of 39.5%, operating margin of 12.9%, and net margin of 9.3%. The key items likely under scrutiny are whether that 2026 outlook increase is sustainable, whether tariff and input costs compress the 12.9% operating margin, and whether revenue growth can hold near the recent 5.8% pace without further EPS deterioration.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GEHC with WhyIHold
Get a plain-English explanation the next time GE HEALTHCARE TECHNOLOGY makes a big move — so you know whether it's benign or worth your attention.